JP2019512207A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512207A5
JP2019512207A5 JP2018536458A JP2018536458A JP2019512207A5 JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5 JP 2018536458 A JP2018536458 A JP 2018536458A JP 2018536458 A JP2018536458 A JP 2018536458A JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512207A (ja
JP7022067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013511 external-priority patent/WO2017124001A2/en
Publication of JP2019512207A publication Critical patent/JP2019512207A/ja
Publication of JP2019512207A5 publication Critical patent/JP2019512207A5/ja
Application granted granted Critical
Publication of JP7022067B2 publication Critical patent/JP7022067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536458A 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 Expired - Fee Related JP7022067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278815P 2016-01-14 2016-01-14
US62/278,815 2016-01-14
PCT/US2017/013511 WO2017124001A2 (en) 2016-01-14 2017-01-13 T cell receptor-like antibodies specific for foxp3-derived peptides

Publications (3)

Publication Number Publication Date
JP2019512207A JP2019512207A (ja) 2019-05-16
JP2019512207A5 true JP2019512207A5 (enExample) 2020-02-20
JP7022067B2 JP7022067B2 (ja) 2022-02-17

Family

ID=59311684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536458A Expired - Fee Related JP7022067B2 (ja) 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体

Country Status (5)

Country Link
US (1) US11505599B2 (enExample)
EP (1) EP3402518A4 (enExample)
JP (1) JP7022067B2 (enExample)
CN (1) CN109069627A (enExample)
WO (1) WO2017124001A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108337890B (zh) * 2015-06-23 2021-10-15 纪念斯隆-凯特琳癌症中心 新型pd-1免疫调节剂
MY194628A (en) 2015-10-23 2022-12-07 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
CN112041432A (zh) * 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
EP3954707A1 (en) * 2018-12-21 2022-02-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022221669A1 (en) * 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
EP4661902A1 (en) * 2023-02-06 2025-12-17 Memorial Sloan-Kettering Cancer Center Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof
WO2025145063A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
EP1937814A4 (en) * 2005-09-01 2010-05-05 Ca Nat Research Council ANTIAPOPTOTIC PROTEIN ANTIBODY
US8420791B2 (en) 2006-11-27 2013-04-16 Ludwig Institute For Cancer Research Ltd. Expression of FoxP3 by cancer cells
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
WO2009003489A1 (en) * 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
EP2020419A1 (en) 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Anti ephB4 antibody fragments
CN101970483A (zh) * 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
US8540987B2 (en) * 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
EP2271760A2 (en) 2008-04-29 2011-01-12 Monsanto Technology LLC Genes and uses for plant enhancement
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
WO2010099083A1 (en) * 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG10201608138RA (en) * 2011-02-01 2016-11-29 Genmab As Human antibodies and antibody-drug conjugates against cd74
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
AU2013267161A1 (en) * 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
EP2897631A4 (en) * 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
SG10201912797XA (en) * 2013-12-24 2020-02-27 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody

Similar Documents

Publication Publication Date Title
JP2019512207A5 (enExample)
CN107405397B (zh) 抗tim-3抗体
JP2020501531A5 (enExample)
CN110891650A (zh) 制导和导航控制蛋白及其制造和使用方法
KR20180114218A (ko) 항-lag-3 항체
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
CN108337890A (zh) 新型pd-1免疫调节剂
JP2019524693A5 (enExample)
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
JP2017535257A5 (enExample)
CN107428832A (zh) 抗pd‑l1抗体
JP2013506428A5 (enExample)
JP2017510251A (ja) 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
JP2018500014A5 (enExample)
CN116948035A (zh) 多特异性抗体及其制备和使用方法
CN117946278A (zh) 多特异性抗体及其制备和使用方法
JP2020530859A (ja) 免疫調節剤としてのｃｄ９６結合剤
CN112292399A (zh) 抗cd27抗体及其用途
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
WO2021121373A1 (zh) 抗人程序死亡因子-1单克隆抗体
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
JP2016529213A5 (enExample)
Sandeep et al. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
AU2018370120A1 (en) Methods for selective expansion of d3 yd T-cell populations and compositions thereof
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防